We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,918,777 | 16:29:57 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
From Apr 2019 to Apr 2024
By Erin McCarthy
Impax Laboratories Inc. (IPXL) said the U.S. Food and Drug Administration issued several inspectional observations after inspecting the company's Taiwan facility for the Parkinson's treatment Rytary.
The FDA performed the general inspection and a preapproval inspection for the treatment earlier this month. The agency issued 10 observations from the inspection, and the company will respond to them within 15 business days, Impax said.
Shares dropped more than 17% in premarket trading.
It is unknown what impact the inspection will have on Rytary's October review date, and the FDA will not reveal the classification or status of the observations until it has received the company's response, Impax added.
Impax in April resubmitted its new drug application for the Parkinson's disease treatment to the FDA with updated safety and stability information. Rytary, a long-gestating drug, hasn't been approved or licensed in any country. Impax first submitted a new drug application for Rytary to the FDA in December 2011.
Last year, Impax and GlaxoSmithKline PLC (GSK) terminated their partnership to develop and market Rytary outside the U.S. and Taiwan following delays in regulatory approval.
Write to Erin McCarthy at erin.mccarthy@wsj.com
Access Investor Kit for GlaxoSmithKline Plc
Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=GB0009252882
Access Investor Kit for GlaxoSmithKline Plc
Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=US37733W1053
Access Investor Kit for Impax Laboratories, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=US45256B1017
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
